Glenmark Life Sciences Ltd

Glenmark Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glenmark Life Sciences Ltd

₹ 1,085 0.06%
21 Nov 4:00 p.m.
glenmarklifesciences.com BSE: 543322 NSE: GLS
About

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Key Points

History
Prior to 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated out of GPL into GLS through a Business Transfer Agreement in Jan 2019. GLS was listed on NSE & BSE in FY22. [1]

Website BSE NSE
  • Market Cap ₹ 13,276 Cr.
  • Current Price ₹ 1,085
  • High / Low ₹ 1,335 / 620
  • Stock P/E 31.4
  • Book Value ₹ 207
  • Dividend Yield 2.07 %
  • ROCE 28.1 %
  • ROE 21.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.7%
  • Company has been maintaining a healthy dividend payout of 76.8%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap Nifty Total Market Nifty Microcap 250 BSE Healthcare BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
562 522 514 490 509 541 621 578 595 573 537 589 507
394 376 372 343 366 395 415 385 428 400 395 429 373
Operating Profit 167 146 142 147 144 145 206 193 167 173 141 159 134
OPM % 30% 28% 28% 30% 28% 27% 33% 33% 28% 30% 26% 27% 27%
2 4 5 9 10 7 3 2 5 2 3 5 9
Interest 7 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 10 10 10 10 10 11 12 13 13 13 15 14 15
Profit before tax 153 140 138 146 144 141 198 182 159 161 130 150 127
Tax % 24% 26% 28% 26% 26% 26% 26% 26% 25% 26% 24% 26% 25%
115 104 99 109 107 105 146 135 119 119 98 111 95
EPS in Rs 9.40 8.46 8.07 8.87 8.72 8.57 11.95 11.05 9.69 9.69 7.99 9.10 7.78
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
0 886 1,537 1,885 2,123 2,161 2,283 2,205
0 638 1,064 1,294 1,506 1,518 1,608 1,597
Operating Profit -0 248 473 592 617 643 675 608
OPM % -4% 28% 31% 31% 29% 30% 30% 28%
0 -0 11 0 14 28 11 19
Interest 0 1 34 88 28 1 2 1
Depreciation 0 19 29 33 38 42 53 57
Profit before tax -0 228 421 471 565 629 631 568
Tax % 4,200% 14% 26% 25% 26% 26% 25%
-0 196 313 352 419 467 471 424
EPS in Rs -430.00 997.86 1,597.37 358.74 34.17 38.11 38.43 34.56
Dividend Payout % 0% 0% 0% 0% 61% 110% 59%
Compounded Sales Growth
10 Years: %
5 Years: 21%
3 Years: 7%
TTM: -6%
Compounded Profit Growth
10 Years: %
5 Years: 19%
3 Years: 10%
TTM: -16%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 21%
1 Year: 73%
Return on Equity
10 Years: %
5 Years: 31%
3 Years: 24%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.01 2 2 2 25 25 25 25
Reserves -1 86 400 751 2,030 2,114 2,308 2,514
0 0 0 0 3 19 17 16
1 1,387 1,324 1,244 414 545 501 530
Total Liabilities 0 1,475 1,726 1,997 2,471 2,702 2,850 3,085
0 456 546 573 590 781 805 821
CWIP 0 80 11 14 97 62 106 141
Investments 0 0 0 0 0 0 0 0
0 939 1,169 1,410 1,784 1,860 1,939 2,122
Total Assets 0 1,475 1,726 1,997 2,471 2,702 2,850 3,085

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-0 10 195 388 598 306 414
0 -9 -51 -69 -122 -147 -116
0 1 -137 -214 -79 -388 -279
Net Cash Flow 0 2 8 106 397 -228 18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 44 185 152 120 116 136 122
Inventory Days 162 441 227 214 185 224 251
Days Payable 41 201 111 92 110 158 139
Cash Conversion Cycle 165 424 268 241 190 202 235
Working Capital Days -2,059 -186 -37 12 150 177 188
ROCE % 529% 186% 97% 42% 30% 28%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 75.00%
8.32% 8.12% 7.58% 6.04% 4.45% 3.28% 3.27% 4.39% 4.57% 5.01% 4.81% 7.85%
0.47% 0.56% 0.79% 0.79% 0.08% 0.00% 0.58% 0.64% 0.74% 1.41% 1.57% 4.16%
8.36% 8.47% 8.78% 10.31% 12.62% 13.86% 13.30% 12.13% 11.84% 10.73% 10.76% 12.99%
No. of Shareholders 2,53,7262,38,5782,33,5382,32,2032,25,7302,22,8662,08,2671,98,7641,85,5311,56,1831,49,3961,43,960

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls